Header Logo

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Michael Leo and Sheila Weinmann.
Connection Strength

0.843
  1. Validation of a Ductal Carcinoma In Situ Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy. Clin Cancer Res. 2020 08 01; 26(15):4054-4063.
    View in: PubMed
    Score: 0.181
  2. External validation of the EORTC and NCCN bladder cancer recurrence and progression risk calculators in a U.S. community-based health system. Urol Oncol. 2020 02; 38(2):39.e21-39.e27.
    View in: PubMed
    Score: 0.176
  3. Validation of a Genomic Classifier for Predicting Post-Prostatectomy Recurrence in a Community Based Health Care Setting. J Urol. 2016 06; 195(6):1748-53.
    View in: PubMed
    Score: 0.134
  4. Comparing direct medical care costs of patients with bladder cancer who received an ileal conduit vs. neobladder in the year following cystectomy. Urol Oncol. 2024 Oct 14.
    View in: PubMed
    Score: 0.062
  5. A 7-Gene Biosignature for Ductal Carcinoma in situ of the Breast Identifies Subpopulations of HER2-positive Patients With Distinct Recurrence Rates After Breast-Conserving Surgery and Radiation Therapy. Clin Breast Cancer. 2024 Sep 04.
    View in: PubMed
    Score: 0.061
  6. A Novel Biosignature Identifies Patients With DCIS With High Risk of Local Recurrence After Breast Conserving Surgery and Radiation Therapy. Int J Radiat Oncol Biol Phys. 2023 01 01; 115(1):93-102.
    View in: PubMed
    Score: 0.054
  7. Predicting risk of multiple levels of recurrence and progression after initial diagnosis of nonmuscle-invasive bladder cancer in a multisite, community-based cohort. Cancer. 2021 02 15; 127(4):520-527.
    View in: PubMed
    Score: 0.047
  8. The effect of multiple recruitment contacts on response rates and patterns of missing data in a survey of bladder cancer survivors 6 months after cystectomy. Qual Life Res. 2020 Apr; 29(4):879-889.
    View in: PubMed
    Score: 0.044
  9. Clinical Use Cases for a Tool to Assess Risk in Superficial Bladder Cancer. Perm J. 2019; 23.
    View in: PubMed
    Score: 0.043
  10. Factors That Influence Selectionof Urinary Diversion Among Bladder Cancer Patients in 3 Community-based Integrated Health Care Systems. Urology. 2019 Mar; 125:222-229.
    View in: PubMed
    Score: 0.041

© 2024 Kaiser Permanente